Clinical Scorecard: Blood Tau Trajectories Tied to Alzheimer's Onset
At a Glance
| Category | Detail |
|---|---|
| Condition | Alzheimer's Disease |
| Key Mechanisms | Longitudinal measurements of plasma phosphorylated tau (p-tau217) associated with symptom onset timing. |
| Target Population | Cognitively unimpaired individuals at risk for Alzheimer's disease. |
| Care Setting | Research or clinical trial settings. |
Key Highlights
- p-tau217 positivity correlates with age at symptom onset.
- Median absolute errors in predicting symptom onset are approximately 3 to 4 years.
- Later p-tau217 positivity leads to quicker progression to symptoms.
- Models utilize repeated measurements for individualized biomarker trajectories.
- Not recommended for individual prognostication outside research settings.
Guideline-Based Recommendations
Diagnosis
- Use plasma %p-tau217 values relative to amyloid PET Centiloid thresholds.
Management
- Biomarker testing in cognitively unimpaired individuals is not recommended outside research.
Monitoring & Follow-up
- Longitudinal tracking of p-tau217 levels may inform clinical trial design.
Risks
- Prediction error too large for clinical decision-making.
Patient & Prescribing Data
Cognitively unimpaired individuals at risk for Alzheimer's.
Models may help enrich clinical trial enrollment.
Clinical Best Practices
- Incorporate repeated measurements for more accurate biomarker trajectories.
- Utilize models for clinical trial design rather than individual prognostication.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
